Knowledge mapping and research trends of cathelicidin peptide LL-37 from 1995 to 2024: a bibliometric study.
Shi. Hongxin H; Shu. Peizhou P; Wang. Zhihao Z; Meng. Chen C; Yu. Rao R; Xu. YongQing Y; Li. Chuan C
Key Findings
- Publications on LL‑37 have steadily increased from 1995‑2024
- The United States and Sweden are the top publishing countries
- PLOS One is the journal with the most LL‑37 papers
- Research on LL‑37’s role in cancer and mast cells is emerging
Practical Outcomes
- For biohackers, the main takeaway is that LL‑37 is still mostly a research topic, not a proven supplement or therapy. Watch future studies, especially those linking LL‑37 to cancer or immune cell function, before considering any real‑world use.
Summary
This paper doesn’t test LL‑37 itself – it just looks at how many studies have been published about it and what topics are getting attention. It shows research on LL‑37 is growing, especially in the US and Sweden, and that cancer‑related work is becoming a hot area.
Abstract
To conduct a comprehensive bibliometric analysis of LL-37, summarize its development trends and patterns, and identify emerging research hotspots. Bibliometric and Knowledge Graph Analysis of Literature Data Related to LL-37 in the WOSCC Database Using Citespace and Vosviewer. A total of 2,814 articles were analyzed, revealing a steady increase in recent publications. The USA and Sweden were the main contributors, with PLOS One publishing the most articles. Research on LL-37 in cancer and mast cells is emerging as a new focus. The research status and development trends of LL-37 were quantitatively analyzed, providing new directions for future studies.
Study Information
pubmed
2025
2025-03-13T00:00:00.000Z
10.1080/10255842.2025.2477218
50